News

President Donald Trump signed an executive order to boost domestic drug manufacturing, ahead of planned tariffs on imported pharmaceuticals. The move aims to reduce reliance on countries like China and Europe, where production costs are lower.

In a recent segment on Zee Business, Managing Editor Anil Singhvi analyzed the impact of  Trump’s new executive order. The move could alter global dynamics and Singhvi pointed out how Indian pharma stocks might respond.

Indian pharma shares opened on  a low after U.S. President Donald Trump signed an executive order to boost domestic drug production, triggering fears of export disruption. The Nifty Pharma index dropped 1.4 per cent, with Lupin and Aurobindo sliding over 3 per cent. The order directs the FDA to fast-track U.S.-made drug approvals and tighten oversight of foreign plants. Trump also hinted at upcoming tariffs on imported medicines, escalating concerns for top Indian exporters like Sun Pharma, Cipla, and Dr Reddy’s.

Trump’s order seeks to expand pharmaceutical production within the U.S., speed up FDA approvals for American plants, and raise inspection fees for foreign manufacturing units. This policy direction signals a push toward greater self-sufficiency in the U.S. healthcare supply chain.

“Trump’s style is direct support domestic industry while making it more expensive for global competitors,” Singhvi highlighted.

Companies like Dr. Reddy’s, Lupin, and Cipla, which rely heavily on U.S. exports, could face pressure in the short term due to potential regulatory burdens and increased costs. However, Singhvi emphasized that political sensitivity around drug prices in the U.S. could prevent Trump from imposing direct tariffs.

“Healthcare is one area where voters are deeply affected. No government wants to be blamed for rising medicine costs,” he explained.

Despite the cautious outlook, Singhvi highlighted Glenmark as a company showing promise amid sector volatility. “If the pharma sector stabilizes or turns positive, Glenmark could lead the recovery. There’s some good news surrounding it,” he noted.

Singhvi advised investors to monitor sentiment and policy clarity closely. “The market is reacting more to expectations than fundamentals right now. Stay nimble, stay informed,” he concluded.

For full analysis and ongoing updates, tune in to Zee Business with Anil Singhvi.

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.